Supernus Pharmaceuticals, Inc. Contracts & Agreements

Settlement Agreement, dated as of April 30, 2024, by and between Supernus Pharmaceuticals, Inc. and Ascent Pharmaceuticals, Inc (Filed With SEC on August 6, 2024)

Form of Executive Retention Agreement (Filed With SEC on February 27, 2024)

Form of Time-Based Incentive Stock Option Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on February 27, 2024)

Form of Non-Statutory Time-Based Stock Option Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on February 27, 2024)

Form of Restricted Stock Unit Award Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on February 27, 2024)

Form of Performance Share Unit Award Agreement, for awards issued after 2023 under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on February 27, 2024)

Settlement Agreement, dated as of June 21, 2023, by and between Supernus Pharmaceuticals, Inc. with Apotex Inc. and Apotex Corp (Filed With SEC on February 27, 2024)

Settlement Agreement, dated as of December 31, 2022, by and between Supernus Pharmaceuticals, Inc., Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (Filed With SEC on March 9, 2023)

Exhibit 10.1 Credit Line Agreement between UBS Bank USA and Supernus Pharmaceuticals, Inc. dated as of February 8, 2023 (Filed With SEC on February 14, 2023)

Amendment to Deed of Lease, August 23, 2021, by and between Supernus Pharmaceuticals, Inc. and Key West MD Owner, LLC (Filed With SEC on November 5, 2021)

Agreement and Plan of Merger, dated as of October 10, 2021, by and among Supernus Pharmaceuticals, Inc., Supernus Reef, Inc. and Adamas Pharmaceuticals, Inc (Filed With SEC on October 12, 2021)

Commercial Supply Agreement, dated May 12, 2021, by and between Supernus Pharmaceuticals, Inc. and Catalent Pharma Solutions, LLC (Filed With SEC on August 6, 2021)

API Supply Agreement, dated July 13, 2021, by and between Supernus Pharmaceuticals, Inc. and Bachem Americas, Inc (Filed With SEC on August 6, 2021)

Form of Time-Based Incentive Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Form of Non-Statutory Time-Based Stock Option Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Form of Restricted Stock Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Form of Performance Share Unit Award Agreement, under the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (Filed With SEC on August 6, 2021)

Exhibit 10.1+ Offer Letter to Timothy C. Dec (Filed With SEC on July 29, 2021)

Asset Purchase and Contribution Agreement, dated as of December (Filed With SEC on March 8, 2021)

Guanfacine License Agreement, dated as of December 22, 2005, by and among the Registrant, Shire LLC and Shire plc, as amended (Filed With SEC on March 8, 2021)

Exclusive License Agreement, dated as of June 6, 2006, by and between the Registrant and United Therapeutics Corporation (Filed With SEC on March 8, 2021)

Purchase and Sale Agreement, dated as of June 9, 2006, by and between the Registrant and Rune HealthCare Limited (Filed With SEC on March 8, 2021)

Consulting Agreement, made as of November 18, 2020, by and between the Company (Filed With SEC on November 19, 2020)

Consulting Agreement, made as of December 31, 2020, by and between the Company (Filed With SEC on November 19, 2020)

Offer Letter to James P. Kelly (Filed With SEC on October 5, 2020)

EXECUTIVE RETENTION AGREEMENT (Filed With SEC on October 5, 2020)

Exhibit 10.1+ Form of Restricted Stock Unit Award Agreement for Non-Management Directors, issued under the Supernus Pharmaceuticals, Inc., 2012 Equity Incentive Plan, as amended,... (Filed With SEC on February 27, 2020)

Exhibit 10.2+ Form of Performance Share Unit Award Agreement, issued under the Amended and Restated Stock Incentive Plan, for grants made to Jack A. Khattar, as an Exhibit... (Filed With SEC on February 27, 2020)

Press Release Dated September 25, 2019 (Filed With SEC on September 25, 2019)

Press Release Dated August 26, 2019 (Filed With SEC on August 26, 2019)

Press Release Dated July 23, 2019 (Filed With SEC on July 23, 2019)

Lease Agreement Dated January 31, 2019 (Filed With SEC on February 5, 2019)

Agreement and Plan of Merger, dated September 12, 2018, by and between Supernus Pharmaceuticals, Inc., Supernus Merger Sub, Inc., Biscayne Neurotherapeutics, Inc. and Reich... (Filed With SEC on November 9, 2018)

Third Amendment to Amended and Restated Employment Agreement, dated May 8, 2018, between Supernus Pharmaceuticals, Inc. and Jack Khattar (Filed With SEC on May 11, 2018)

Form of Amendment to Executive Retention Agreement (Filed With SEC on May 11, 2018)

Purchase Agreement, dated March 14, 2018, among Supernus Pharmaceuticals, Inc. and Jefferies LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC (Filed With SEC on March 20, 2018)

Indenture, dated as of March 19, 2018, between Supernus Pharmaceuticals, Inc. and Wilmington Trust, National Association, as trustee (Filed With SEC on March 20, 2018)

Base Convertible Bond Hedge Transaction, dated March 14, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Base Convertible Bond Hedge Transaction, dated March 14, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Base Convertible Bond Hedge Transaction, dated March 14, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Base Issuer Warrant Transaction, dated March 14, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Base Issuer Warrant Transaction, dated March 14, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Base Issuer Warrant Transaction, dated March 14, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Additional Convertible Bond Hedge Transaction, dated March 15, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Additional Convertible Bond Hedge Transaction, dated March 15, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Additional Convertible Bond Hedge Transaction, dated March 15, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Additional Issuer Warrant Transaction, dated March 15, 2018, between Deutsche Bank AG, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Additional Issuer Warrant Transaction, dated March 15, 2018, between Bank of America, N.A. and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Additional Issuer Warrant Transaction, dated March 15, 2018, between JPMorgan Chase Bank, National Association, London Branch and Supernus Pharmaceuticals, Inc (Filed With SEC on March 20, 2018)

Lease Agreement Dated February 27, 2018 (Filed With SEC on March 5, 2018)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. (Filed With SEC on May 9, 2017)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. (Filed With SEC on March 9, 2016)

SECOND AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 4, 2016)

FOURTH AMENDMENT TO LEASE (Filed With SEC on October 24, 2014)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on October 24, 2014)

EXECUTIVE RETENTION AGREEMENT (Filed With SEC on September 18, 2014)

EXECUTIVE RETENTION AGREEMENT (Filed With SEC on August 11, 2014)

SUPERNUS PHARMACEUTICALS, INC. AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 11, 2014)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. (Filed With SEC on July 8, 2014)

SECURITY AGREEMENT (Filed With SEC on July 8, 2014)

Supernus to Receive $30 Million in Non-Dilutive Royalty Deal (Filed With SEC on July 8, 2014)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on October 24, 2013)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. (Filed With SEC on August 21, 2013)

LEASE AGREEMENT (Filed With SEC on March 15, 2013)

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. COMMERCIAL SUPPLY AGREEMENT (Filed With SEC on February 7, 2013)

[] Shares Supernus Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on November 26, 2012)

OFFER LETTER TO EXECUTIVE OFFICER (Filed With SEC on November 2, 2012)

COMPENSATORY ARRANGEMENTS WITH EXECUTIVE OFFICERS (Filed With SEC on November 2, 2012)

AMENDMENT NO. 2 TO STOCKHOLDERS VOTING AGREEMENT (Filed With SEC on April 27, 2012)

STOCK RESTRICTION AGREEMENT (Filed With SEC on April 27, 2012)

AMENDMENT NO. 2 TO STOCK RESTRICTION AGREEMENT (Filed With SEC on April 27, 2012)

Supernus Pharmaceuticals, Inc. [ ] Shares Common Stock ($0.001 par value) Underwriting Agreement (Filed With SEC on April 11, 2012)

STOCKHOLDERS VOTING AGREEMENT (Filed With SEC on April 11, 2012)

SUPERNUS PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN (Filed With SEC on April 11, 2012)

SUPERNUS PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH... (Filed With SEC on April 11, 2012)

SUPERNUS PHARMACEUTICALS, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on April 11, 2012)

AMENDMENT NO. 2 TO INVESTOR RIGHTS AGREEMENT (Filed With SEC on April 11, 2012)

ASSET PURCHASE AND CONTRIBUTION AGREEMENT dated as of December 22, 2005 among SUPERNUS PHARMACEUTICALS, INC., SHIRE LABORATORIES INC. and SHIRE PLC (Filed With SEC on March 16, 2012)

GUANFACINE LICENSE AGREEMENT (Filed With SEC on March 16, 2012)

EXCLUSIVE OPTION AND LICENSE AGREEMENT (Filed With SEC on March 16, 2012)

PURCHASE AND SALE AGREEMENT (Filed With SEC on March 16, 2012)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 16, 2012)

Supernus Pharmaceuticals, Inc. 1550 East Gude Drive, Rockville, MD 20850 USA Phone: (301) 838-2500 Fax: (301) 838-2501 www.supernuspharma.com (Filed With SEC on March 16, 2012)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 16, 2012)

CONSULTING AGREEMENT (Filed With SEC on March 16, 2012)

AMENDED AND RESTATED WARRANT TO PURCHASE STOCK (Filed With SEC on February 14, 2012)

SECURED PROMISSORY NOTE - 1 (Term B Loan) (Filed With SEC on February 14, 2012)

SECURED PROMISSORY NOTE - 2 (Term B Loan) (Filed With SEC on February 14, 2012)

SECURED PROMISSORY NOTE (Term B Loan) (Filed With SEC on February 14, 2012)

WARRANT TO PURCHASE STOCK (Filed With SEC on February 14, 2012)

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on February 14, 2012)

UNIT PURCHASE AGREEMENT dated as of December 14, 2011 by and between SUPERNUS PHARMACEUTICALS, INC., and ROYALTY OPPORTUNITIES S.r.I (Filed With SEC on February 14, 2012)

FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on February 14, 2012)

SECURED PROMISSORY NOTE (Filed With SEC on February 8, 2011)

WARRANT TO PURCHASE STOCK (Filed With SEC on February 8, 2011)

ASSET PURCHASE AND CONTRIBUTION AGREEMENT dated as of December 22, 2005 among SUPERNUS PHARMACEUTICALS, INC., SHIRE LABORATORIES INC. and SHIRE PLC (Filed With SEC on February 8, 2011)

GUANFACINE LICENSE AGREEMENT (Filed With SEC on February 8, 2011)

EXCLUSIVE OPTION AND LICENSE AGREEMENT (Filed With SEC on February 8, 2011)

PURCHASE AND SALE AGREEMENT (Filed With SEC on February 8, 2011)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on February 8, 2011)

INDENTURE dated as of April 15, 2008 by and between TCD ROYALTY SUB LLC, a Delaware limited liability company, as issuer of the Notes described herein, and U.S. BANK NATIONAL... (Filed With SEC on February 8, 2011)

LOAN AND SECURITY AGREEMENT (Filed With SEC on February 8, 2011)

SUPERNUS PHARMACEUTICALS, INC. 2005 STOCK PLAN, AS OF DECEMBER 22, 2005 (PURSUANT TO BOARD RESOLUTION AND SHAREHOLDER CONSENT AS OF DECEMBER 21, 2005) (Filed With SEC on December 23, 2010)

Confidential SUPERNUS PHARMACEUTICALS, INC. SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN (Filed With SEC on December 23, 2010)

EMPLOYMENT AGREEMENT (Filed With SEC on December 23, 2010)

SUPERNUS PHARMACEUTICALS, INC. STOCK RESTRICTION AGREEMENT (Filed With SEC on December 23, 2010)

Shire Laboratories Lease STANDARD FORM MULTI-TENANT NET LEASE (Non-California) (Filed With SEC on December 23, 2010)

FIRST AMENDMENT TO LEASE (Filed With SEC on December 23, 2010)

SECOND AMENDMENT TO LEASE (Filed With SEC on December 23, 2010)

THIRD AMENDMENT TO LEASE (Filed With SEC on December 23, 2010)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on December 23, 2010)

Category

Industry

Companies

Contracts

Supernus Pharmaceuticals, Inc. Contracts & Agreements